FOXP3 and non-small cell lung carcinoma: There was no significant difference between the percentages of CD4+CD25+FoxP3+ or CD4+CD25highFoxP3+ Treg in NSCLC patients and HDs (29.04 ± 2.8% versus 35.46 ± 6.2%; p = 0.1 and 47.09 ± 2.8% versus 54.81 ± 5.9%; p = 0.3, respectively, Fig. 1C,D).